About

Bobby W. Sandage, Jr., Ph.D. has over 40 years of experience in the pharmaceutical industry in drug development and senior management and over 10 years in venture capital investing and currently holds positions in the St. Louis area as Managing Director of the Paula and Rodger Riney Foundation and Lightchain Capital, a venture fund, and is a General Partner in Cultivation Capital Life Sciences Fund II, also a venture fund.

Previously Dr. Sandage was President and CEO of Euclises Pharmaceuticals, at St. Louis based start-up biotech company.  He was also President and Chief Executive Officer of Coronado BioSciences, Inc. an immunotherapy company where he took the company public in 2011.  Prior to that, he was Vice President of Covidien (Mallinckrodt) Pharmaceuticals’ oncology research and development program.  For 19 years, Dr. Sandage was the Chief Scientific Officer and Executive Vice President of Research and Development, Quality and Manufacturing at Indevus Pharmaceuticals, Inc. which was acquired by Endo Pharmaceuticals in 2009. Prior to Indevus, he held senior drug development positions at DuPont Merck Pharmaceutical Company, DuPont/American Critical Care, Merrell Dow and Dow Pharmaceuticals. 

Dr. Sandage has extensive experience guiding numerous life sciences companies as a Member of the Board of Directors of NextRNA, Microbial Machines, Immunophotonics and Endevica Bio. He was previously a member of the Board Directors at public companies Mateon, Gentium S.r.l., Osteologix, Inc. and Genta along with private companies Arch Oncology, AI Proteins and Geneoscopy.

Dr. Sandage received his undergraduate degree in Pharmacy from the University of Arkansas and his Ph.D. in Clinical Pharmacy from Purdue.